HPV AND CERVICAL CANCER IN MOLODVA COST/BENEFIT ANALYSIS



Andrzej Jarynowski

Jagiellonian Univ. in Cracow/ Moldova State Univ. In Kishinev

polska pomoc



- HPV (sexualy transmittable virus) Cervical cancer
- Cervical cancer: first most common type of cancer in working age women in Moldova
- Control: a combination of vaccination and screening
- Scenarios: demographic change, increase of sexuality, screening freq.

<3.1 <3.9 <5.2 <7.4 <13.0</p>
Mortality of cervical cancer





My questions for next 15-20 years

- The optimal preventive guidelines: cervical **screening** practice, targeted vaccination and sexual education


- Costs of HPV vaccination, **screening**, treatment and preventive program.







Spread of HPV & Cancer development & living Moldovan society



Set of differential and stochastic equations

Ö,

-Ö

o c


Q

00


Ö.

Ö-

റ്




Population (15-65)







Incidence of new cancer case estimated for historical data (1998-2012) and possible projections till 2031








Screening guideline in Moldova since 2012: Target group: >20 years old women


Frequency: every 2 years

It sounds great (better than in the world richerst counties), **however**

Public heath system in Moldova has no capacity to couple with official screening program, where more than 700k test suppose to be done yearly (currently it's 100k and in many sites it seems to be already overloaded). It's more than 3.5 M EUR yearly according to this theoretical program.



Age group (years)






We examine overall cancer costs for:

- current screening program +20 (scr2)
- 25-64 (scr1) 100-300k EUR yearly

cost: 10-15 additional cancer cases yearly


Net gain





Approaching 5 years effective screening intervals







Conclusions



- Moldova has no capacity to apply official screening program, where more than 700k test suppose to be done yearly (currently it's 100k and in many sites it seems to be already overloaded);
- The saving perspective in 10-15 years would in range 100-300k EUR yearly with almost no population costs;
- Targeted vaccination and sexual education have similar finacial costs (in long perspective) like frequent screening, but provide more populational profits.



th.if.uj.edu.pl/~gulakov andrzej.jarynowski@sociology.su.se